AOD-9604 Patent Status and Generic Timeline

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide consisting of the C-terminal fragment (amino acids 176-191) of human growth hormone, with an added tyrosine residue at its N-terminus. It was developed by Metabolic Pharmaceuticals Ltd. in Australia during the late 1990s as a potential anti-obesity agent that could mimic the lipolytic effects of growth hormone without triggering its diabetogenic or growth-promoting actions.

The foundational preclinical work by Heffernan et al. (2001) demonstrated that this fragment stimulated lipolysis in adipose tissue explants from both ob/ob mice and human subjects without activating the growth hormone receptor [1]. This was a meaningful distinction. Full-length GH causes insulin resistance through IGF-1-mediated pathways, but AOD-9604 appeared to bypass that mechanism entirely, acting through a beta-3 adrenergic-adjacent pathway that had not been fully characterized at the time of publication.

Metabolic Pharmaceuticals pursued AOD-9604 through Phase IIb clinical trials for obesity in Australia. The Phase IIb trial enrolled approximately 300 obese subjects and tested oral formulations at doses of 1 mg, 5 mg, and 25 mg daily over 24 weeks [2]. The results were modest. Mean weight loss did not reach statistical significance over placebo in the primary endpoint, and the program was discontinued before reaching Phase III. The company entered voluntary administration in 2008.

How AOD-9604 Works at the Molecular Level

The peptide's mechanism centers on lipolysis activation in white adipose tissue without engaging the somatotropic axis. Full-length human growth hormone binds the GH receptor (GHR) as a dimer, triggering JAK2-STAT5 signaling that drives both lipolysis and IGF-1 secretion. AOD-9604 cannot form this dimer. It lacks the receptor-binding domains in the N-terminal half of GH.

Instead, preclinical data suggest AOD-9604 stimulates hormone-sensitive lipase (HSL) activity through a mechanism that may involve beta-3 adrenergic receptor co-signaling, though the exact binding target remains unidentified [1]. In the Heffernan et al. study, the fragment increased glycerol release from adipose explants by 40-60% compared to controls, a marker of triglyceride hydrolysis. Fat oxidation increased without changes in serum IGF-1, fasting glucose, or insulin levels in animal models.

This separation of lipolytic from metabolic effects was the entire commercial thesis behind AOD-9604. A peptide that burns fat without worsening insulin resistance would fill a gap that recombinant GH cannot. The problem was that the effect size in humans proved too small to support regulatory approval.

The Patent History of AOD-9604

Metabolic Pharmaceuticals filed its foundational composition-of-matter patent for AOD-9604 in 1999. The key US patent (US 6,969,702 B1) covered the peptide itself, methods of use for fat reduction, and specific pharmaceutical formulations. Additional patents covered oral delivery systems that the company hoped would differentiate the product from injectable-only competitors.

The patent portfolio included:

US 6,969,702 B1 covered the composition of the modified hGH fragment 176-191 and its use for reducing body fat. Filed in 1999, this patent carried a standard 20-year term from the filing date. It expired in 2019 [3].

Australian Patent AU 2003204380 covered similar claims in Metabolic Pharmaceuticals' home jurisdiction. This patent also expired, following the same timeline.

Supplementary patents filed between 2001 and 2005 covered oral formulation technologies and combination therapies with other lipolytic agents. These have similarly lapsed.

When Metabolic Pharmaceuticals entered voluntary administration in 2008, the intellectual property was acquired by Calzada Ltd. (later renamed Adalta Ltd.), which did not pursue further clinical development of AOD-9604 for obesity. The peptide's IP effectively became unencumbered by the late 2010s.

One critical point: patent expiration does not equal FDA approval. The expiration of these patents simply means that other manufacturers can legally synthesize AOD-9604 without infringing composition-of-matter claims. It does not create an approved drug product.

Why There Is No Generic AOD-9604

The term "generic" has a specific regulatory meaning under the Hatch-Waxman Act. A generic drug is approved through an Abbreviated New Drug Application (ANDA) that references an existing approved branded product, the Reference Listed Drug (RLD). The ANDA applicant must demonstrate bioequivalence to the RLD [4].

AOD-9604 has no RLD. No company has ever received FDA approval for any AOD-9604 product through the NDA or BLA pathway. Without a branded approved product, no ANDA can be filed. The generic pathway simply does not apply.

This is not unusual for peptides that were developed outside the US and never completed FDA-regulated Phase III trials. Other examples include BPC-157 and various growth hormone-releasing peptides that exist in a similar regulatory gray zone. The FDA's CDER maintains lists of approved drugs, and AOD-9604 does not appear on any of them [5].

For a generic AOD-9604 to exist in the traditional pharmaceutical sense, a sponsor would first need to:

1. File an IND (Investigational New Drug application) with FDA
2. Complete Phase I, II, and III trials under US regulatory standards
3. Submit and receive approval of an NDA or BLA
4. Only then could a second manufacturer file an ANDA referencing that product

No company has publicly disclosed an active IND for AOD-9604 as of May 2026.

Current Access Through 503A Compounding

US patients currently obtain AOD-9604 through 503A compounding pharmacies. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, pharmacies can compound medications for individual patients based on a valid prescription from a licensed prescriber [6].

The 503A pathway requires:

• A patient-specific prescription from a licensed physician, NP, or PA
• The compounded product must not be a copy of a commercially available drug
• The pharmacy must comply with applicable USP compounding standards (USP <797> for sterile preparations)
• The bulk drug substance used must meet compendial or FDA-acceptable quality standards

AOD-9604's position under 503A is legally tenable precisely because no commercially available FDA-approved version exists. A compounding pharmacy is not "copying" an approved product. It is preparing a medication from bulk active pharmaceutical ingredient (API) for an individual patient.

The 503B outsourcing facility pathway tells a different story. The FDA nominated AOD-9604 for review for inclusion on the bulk drug substances list for 503B outsourcing facilities, but it was not added to the approved list [7]. This means large-scale outsourcing facilities cannot legally compound AOD-9604 for office use without individual prescriptions in the way that 503B facilities handle drugs like testosterone cypionate.

The FDA's 2023-2025 Compounding Crackdown and AOD-9604

The FDA's actions against compounded GLP-1 receptor agonists (particularly semaglutide) between 2023 and 2025 sent ripple effects through the peptide compounding market. While AOD-9604 was not directly targeted in the same way as compounded semaglutide, the FDA's updated guidance on compounding raised scrutiny on all peptide compounds [8].

The FDA's position on compounded peptides has three relevant prongs:

Quality concerns. The agency has cited potency variability, sterility failures, and endotoxin contamination in compounded peptide products. A 2023 FDA safety alert documented adverse events from compounded peptides, though these were primarily related to semaglutide salts rather than AOD-9604 specifically [9].

Category III classification. Under the FDA's 503B bulks evaluation framework, substances are classified into three categories. Category 1 substances can be used by 503B facilities. Category 2 substances need more data. Category 3 substances are rejected. AOD-9604 was evaluated but not placed in Category 1, effectively blocking 503B compounding.

Enforcement discretion. The FDA has historically exercised enforcement discretion over 503A compounding when pharmacies comply with state law and USP standards. AOD-9604 remains accessible through this pathway, but the regulatory environment could shift if the FDA issues specific guidance against its compounding.

Projected Timeline: Will AOD-9604 Ever Get FDA Approval?

Predicting an approval timeline requires examining commercial incentives, and they are weak. The Phase IIb data showed insufficient efficacy for obesity. The GLP-1 receptor agonist class (semaglutide, tirzepatide) has dominated the obesity market with 15-20% mean weight loss in key trials [10]. For comparison, AOD-9604's Phase IIb oral formulation showed roughly 2-3 kg of additional weight loss over placebo at 24 weeks [2].

No rational pharmaceutical company would invest the estimated $1-2 billion required for a full NDA program when the efficacy signal is this far behind established competitors. The economics do not support it.

There are three scenarios that could change AOD-9604's regulatory trajectory:

Scenario 1: New indication discovery. If preclinical or early clinical data emerge showing AOD-9604 has meaningful efficacy in a non-obesity indication (such as osteoarthritis, as some preliminary research suggests), a sponsor might pursue a narrower NDA [11]. Cartilage repair is a high-value indication with less competition than obesity.

Scenario 2: 505(b)(2) pathway. A company could potentially use existing published literature and the Australian Phase IIb data to support a 505(b)(2) NDA, which allows reliance on data not generated by the applicant. This would reduce development costs but still require substantial new clinical work.

Scenario 3: No approval. AOD-9604 remains indefinitely in the compounding-only space, similar to dozens of other peptides that have been used clinically without ever achieving NDA approval. This is the most probable outcome based on current market dynamics.

The realistic assessment: absent an unexpected clinical discovery in a new therapeutic area, AOD-9604 is unlikely to receive FDA approval within the next decade.

What This Means for Patients Currently Using AOD-9604

Patients obtaining AOD-9604 through 503A compounding should understand three practical implications of its regulatory status.

First, insurance will not cover it. Without an FDA-approved product and an assigned NDC code recognized by payers, AOD-9604 is a cash-pay medication. Typical out-of-pocket costs range from $150-400 per month depending on the compounding pharmacy and prescribed dose.

Second, quality varies between pharmacies. Unlike FDA-approved drugs manufactured under cGMP with batch-release testing, compounded AOD-9604 quality depends on the individual pharmacy's adherence to USP <797> sterile compounding standards [12]. Patients should verify their pharmacy holds current state board accreditation and ideally PCAB (Pharmacy Compounding Accreditation Board) certification.

Third, the prescribing physician bears clinical responsibility. Because AOD-9604 lacks an FDA-approved labeling with defined dosing, contraindications, and drug interactions, the prescribing clinician must rely on published literature, clinical experience, and patient-specific assessment to guide therapy. The standard compounding dose of 250-300 mcg subcutaneously once daily is based on extrapolation from preclinical and early clinical data, not on FDA-reviewed dose-finding studies.

Patients should have baseline metabolic labs (fasting glucose, insulin, lipid panel, IGF-1) before starting AOD-9604 and repeat monitoring at 8-12 week intervals to assess both efficacy and safety on an individual basis.